1. Home
  2. KSCP vs ACRV Comparison

KSCP vs ACRV Comparison

Compare KSCP & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knightscope Inc.

KSCP

Knightscope Inc.

HOLD

Current Price

$3.44

Market Cap

58.1M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.87

Market Cap

52.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSCP
ACRV
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medicinal Chemicals and Botanical Products
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
52.4M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
KSCP
ACRV
Price
$3.44
$1.87
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$17.00
$11.67
AVG Volume (30 Days)
867.9K
553.5K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
63.54
15.13
EPS
N/A
N/A
Revenue
$11,335,000.00
N/A
Revenue This Year
$218.66
N/A
Revenue Next Year
$54.32
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
4.91
N/A
52 Week Low
$2.92
$1.05
52 Week High
$10.13
$3.56

Technical Indicators

Market Signals
Indicator
KSCP
ACRV
Relative Strength Index (RSI) 43.12 67.02
Support Level $3.09 $1.73
Resistance Level $4.50 $2.47
Average True Range (ATR) 0.34 0.11
MACD -0.05 0.04
Stochastic Oscillator 17.24 86.61

Price Performance

Historical Comparison
KSCP
ACRV

About KSCP Knightscope Inc.

Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: